The 24th JFCR-ISCC

December 11-12, 2019
Miraikan – The National Museum of Emerging Science and Innovation 7F
2-3-6, Aomi, Koto-ku, Tokyo, Japan

The 24th JFCR-ISCC is scheduled as indicated above.
The JFCR-ISCC aims at information exchange on the latest findings of newly developing anti-cancer drugs/therapies and the related topics, including molecularly targeted agents, immune checkpoint inhibitors, immunomodulators and their combinations. These anti-cancer drugs/therapies have been developing prominently with global standards. Meanwhile, already launched molecularly targeted drugs and immune checkpoint inhibitors have often been faced with intrinsic resistance, acquired resistance, and side effects. Accessing to the information is indispensable, moreover, informal exchanges of personal, very specific, or even unsuccessful experiences, are critically valuable for effective achievements of future drug/therapy development. I, as the Chairman of the JFCR-ISCC, believe this Symposium with relatively small size will provide you an excellent opportunity for such communications through personal contacts. 
The topics in the upcoming 24th JFCR-ISCC are Microbiome, TKI/Immunotherapy resistance, Genomic profiling tests, and the First-in-class drugs. I hope the Symposium would be an excellent occasion for you to access the domestic and international developments of novel anti-cancer drugs/therapies, and to meet researchers in academia, hospitals and industries. So, I sincerely welcome your participation in the Symposium.
Looking forward to seeing you in Tokyo!

Naoya Fujita, Ph.D.
Chairman, JFCR-ISCC
Center Director of the Cancer Chemotherapy Center, JFCR

December 11


Poster mounting


Committee meeting (Conference Room Saturn)

Miraikan Hall

Opening Remark


Naoya Fujita (Cancer Chemotherapy Center, JFCR, Tokyo)

Miraikan Hall

I New drugs under clinical or preclinical investigations (1)

Chairpersons: Sergio Quezada (University College London Cancer Institute, London, UK),
Hideaki Kakeya (Kyoto University, Kyoto)


Martijn P. Lolkema (Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands)

Clinical activity, safety, and PK/PD from a Phase 1 study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v): can we revive IL2 for cancer treatment?


Eijiro Nakamura (Kyoto University, Kyoto)

Targeting HIF-2: the novel and ideal approach for the treatment of renal cell carcinoma and VHL-related tumors


Miles Congreve (Sosei Heptares, Cambridge, UK)

Discovery of A2AR antagonist HTL1071/AZD4635 using SBDD




Coffee break

Miraikan Hall

II Microbiome in Tumorigenesis

Chairpersons: Ryan Corcoran (MGH Cancer Center, Boston, MA, USA),
Masanobu Oshima (Kanazawa University, Ishikawa)


Weiping Zou (University of Michigan, Ann Arbor, MI, USA)

Ferroptosis in cancer immunity and therapy


Shinji Fukuda (Keio University, Yamagata)

The impact of gut microbiota-derived metabolites in tumorigenesis



Miraikan Hall

Meet-the-Expert Session

Chairperson: Shunji Takahashi (Cancer Institute Hospital, JFCR, Tokyo)


Hiroshi Nishihara (Keio University, Tokyo)

“PleSSision”; a pathologist edited cancer gene profiling test promotes cancer precision medicine in Japan



Miraikan Hall

Poster Flash Talks

Chairperson: Ryohei Katayama (Cancer Chemotherapy Center, JFCR, Tokyo)


Conference Room Jupiter

Poster Session & Mixer


Nobuko Koshikawa (Chiba Cancer Center Research Institute, Chiba)

Retardation of tumor cell growth by PI polyamide-drug conjugates targeting mtDNA mutation

Takuya Hoshino (Taiho Pharmaceutical Co., Ltd., Ibaraki)

TAS1553, a novel protein-protein interaction inhibitor against RNR, demonstrates antitumor activity via the induction of dATP pool reduction and DNA replication stress

Shingo Noguchi (Daiichi Sankyo Co, Ltd., Tokyo)

Azacitidine (AZA) enhances antileukemic activity of the MDM2 inhibitor milademetan in TP53 wild-type acute myeloid leukemia (AML)

Keiji Funayama (MSD K.K., Tokyo)

Phase 2 study of olaparib in previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002

Takashi Kojima (National Cancer Center Hospital East, Chiba)

Current status of oncolytic virus therapy; especially adenovirus-based therapy

Shinsuke Nakao (Astellas Pharma Inc., Ibaraki)

Antitumor effect of intratumoral IL-7 and IL-12 expression by a tumor-selective oncolytic vaccinia virus in poorly immunogenic murine cancer

Ai Takemoto (Cancer Chemotherapy Center, JFCR, Tokyo)

Development of a humanized anti-podoplanin antibody inhibiting tumor-dependent platelet activation

Ken Okada (FujiFilm Corporation, Kanagawa)

FF-10850, a novel liposomal topotecan, achieved superior anti-tumor effects and a favorable safety profile via preferential distribution followed by dual payload release mechanisms in tumor

December 12

Miraikan Hall

III Tumor heterogeneity and resistance to TKI

Chairpersons: Jaap Verweij (Erasmus Medical Center, Rotterdam, The Netherlands),
Mikihiko Naito (National Institute of Health Sciences, Kanagawa)


Hiromichi Ebi (Aichi Cancer Center, Aichi)

Targeting cancers with aberrant MAPK signal


Ryan Corcoran (MGH Cancer Center, Boston, MA, USA)

Defining novel targeted therapy combination strategies for BRAF V600 mutant colorectal cancer


Seiji Yano (Kanazawa University, Ishikawa)

Drug-tolerant persister cells and AXL




Coffee break

Miraikan Hall

Poster Discussion Session

Chairperson: Manabu Kawada (Institute of Microbial Chemistry, Tokyo)


Mentor 1: Jaap Verweij

Mentor 2: Ryan Corcoran

Conference Room Saturn & Uranus

Luncheon Seminar

Chairperson: Shiro Kitano (Toppan Printing Co., Ltd., Saitama / Osaka Univ., Osaka)


Eiji Shinozaki (Cancer Institute Hosipital, JFCR, Tokyo)

New drug screening system of anticancer agents by Ex vivo 3D culture technology


Poster removal

Miraikan Hall

Special Lecture

Chairperson: Mitsuaki Yoshida (Cancer Chemotherapy Center, JFCR, Tokyo)


Jaap Verweij (Erasmus Medical Center, Rotterdam, The Netherlands)

Benefits and risks of early marketing approval of novel anticancer drugs




Coffee break

Miraikan Hall

IV Molecular Mechanisms underlying Immunotherapy Response

Chairpersons: Weiping Zou (University of Michigan, Ann Arbor, MI, USA),
Hiroyoshi Nishikawa (National Cancer Center, Chiba / Nagoya University, Aichi)


Sergio Quezada (University College London Cancer Institute, London, UK)

Targeting Regulatory T cells for Therapeutic Gain: Means and Mechanisms


Ryohei Katayama (Cancer Chemotherapy Center, JFCR, Tokyo)

Diverse resistance mechanisms to anti-PD-L1 blockade therapy in cancer


Kohei Shitara (National Cancer Center Hospital East, Chiba)

Immune checkpoint blockade and its combination therapy for GI cancers: targeting the immune microenvironment



Miraikan Hall

V New drugs under clinical or preclinical investigations (2)

Chairpersons: Martijn P. Lolkema (Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands),
Hiroyuki Seimiya (Cancer Chemotherapy Center, JFCR, Tokyo)


Erkut Bahceci (Astellas Pharma Global Development, Northbrook, IL, USA)

Development of a small molecule FLT3 inhibitor in AML


Tatsuro Watanabe (Saga University, Saga)

Development of novel orally bioavailable hypomethylating agents



Miraikan Hall

Closing Remark


Jaap Verweij (Erasmus Medical Center, Rotterdam, The Netherlands)

Closing remark

Page Top